- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01851265
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
25. august 2017 oppdatert av: AstraZeneca
A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours.
This is a 2 part study for patients with solid tumours.
The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating 3 different breakfasts (high calorie, regular and none).
In Part B Patients can take olaparib capsules daily and study assessments will be recorded for 6 months (minimum).
Treatment can continue for as long as the patient is benefitting.
Throughout the study patients will be monitored for any side effects.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
32
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Edegem, Belgia, 2650
- Research Site
-
Leuven, Belgia, 3000
- Research Site
-
Wilrijk, Belgia, 2610
- Research Site
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Research Site
-
Maastricht, Nederland, 6202 AZ
- Research Site
-
-
-
-
-
Glasgow, Storbritannia, G12 0YN
- Research Site
-
Manchester, Storbritannia, M20 4BX
- Research Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 130 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients aged ≥18 years, male and female
- Able to eat a high-fat breakfast within a 30-minute period, as provided by the study site
- Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy and for which no suitable effective standard therapy exists
- ECOG performance status ≤2
- Normal organ and bone marrow function measured within 28 days prior to administration of IP as defined in protocol
Exclusion Criteria:
- Participation in another clinical study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used)
- Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment (or a longer period depending on the defined characteristics of the agents used).
- Toxicities (≥CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia
- Patients unable to fast for up to 14 hours or who have type I or type II diabetes
- Patients who have gastric, gastro-oesophageal or oesophageal cancer
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Fasted
Olaparib capsules following no breakfast
|
400mg olaparib capsule formulation taken 30 minutes after allocated meal.
5-14 days between arms.
Allocated breakfast prior to dosing with 400mg olaparib capsules
|
Annen: Standard meal
Olaparib capsules after standard breakfast
|
400mg olaparib capsule formulation taken 30 minutes after allocated meal.
5-14 days between arms.
Allocated breakfast prior to dosing with 400mg olaparib capsules
|
Annen: High Fat
Olaparib capsules after high fat breakfast
|
400mg olaparib capsule formulation taken 30 minutes after allocated meal.
5-14 days between arms.
Allocated breakfast prior to dosing with 400mg olaparib capsules
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pharmacokinetics of Olaparib (Cmax and tmax)
Tidsramme: Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose
|
Rate and extent of absorption of olaparib following single-dose olaparib by assessment of maximum plasma olaparib concentration (Cmax) and time to reach maximum plasma concentration (tmax)
|
Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose
|
Pharmacokinetics of Olaparib (AUC0-t)
Tidsramme: Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.
|
Rate and extent of absorption of olaparib following single-dose olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point (AUC0-t)
|
Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.
|
Pharmacokinetics of Olaparib (AUC)
Tidsramme: Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose
|
Rate and extent of absorption of olaparib following single-dose olaparib by assessment of area under the plasma concentration time curve from zero to infinity (AUC)
|
Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose
|
Pharmacokinetics of Olaparib Pharmacokinetics of Olaparib (CL/F, Vz/F, λz and t½)
Tidsramme: Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.
|
Rate and extent of absorption of olaparib following single-dose olaparib by assessment of apparent clearance following oral administration (CL/F), apparent volume of distribution (Vz/F), terminal rate constant (λz), and terminal half-life (t½)
|
Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety monitoring of Olaparib
Tidsramme: AEs will be collected from signed informed consent up to 30-day post last dose in Part A. For patients in Part B, AE's will be collected until the final patient has completed 6 months in Part B, including 30 day follow up for those who discontinue
|
Assessment of adverse events (AEs), graded by CTCAE (v4.0), physical examination, vital signs (including BP and pulse), standard 12-lead ECG and evaluation of laboratory parameters (clinical chemistry, haematology, and urinalysis).
Assessment of physical examination, vital signs, ECG and evaluation of laboratory parameters will occur at screening, on the day before dosing in each treatment period and 30 days after last dose.
|
AEs will be collected from signed informed consent up to 30-day post last dose in Part A. For patients in Part B, AE's will be collected until the final patient has completed 6 months in Part B, including 30 day follow up for those who discontinue
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Anitra Fielding, AstraZeneca Senior Research Physician
- Hovedetterforsker: Christian Rolfo, UZ Antwerpen
- Studiestol: Wendy Bannister, AstraZeneca Study Statistician
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
4. juli 2013
Primær fullføring (Faktiske)
18. oktober 2013
Studiet fullført (Faktiske)
6. juni 2017
Datoer for studieregistrering
Først innsendt
8. mai 2013
Først innsendt som oppfylte QC-kriteriene
8. mai 2013
Først lagt ut (Anslag)
10. mai 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. august 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. august 2017
Sist bekreftet
1. august 2017
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D081AC00001
- 2013-001255-13 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Solide svulster
-
Albert Einstein College of MedicineAvsluttetKreft | Solid svulst | Metastatisk solid svulst | Metastatisk dMMR solid kreftForente stater
-
Memorial Sloan Kettering Cancer CenterRekrutteringSolid svulst | Solid svulst, voksen | Solid svulst, uspesifisert, voksenForente stater
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid svulst | Solid svulst, voksen | Solid svulst, uspesifisert, voksenForente stater, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid svulst | Solid svulst, voksen | Solid svulst, uspesifisert, voksenForente stater, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRekrutteringKreft | Solid svulst, voksen | Solid karsinom | Solid svulst, uspesifisert, voksen | Kreft Metastatisk | Svulst, solidForente stater
-
RemeGen Co., Ltd.FullførtMetastatisk solid svulst | Lokalt avansert solid svulst | Ikke-opererbar solid svulstAustralia
-
Impact Therapeutics, Inc.RekrutteringSolid svulst | Avansert solid svulstKina, Taiwan, Forente stater, Australia
-
Partner Therapeutics, Inc.TilbaketrukketSolid svulst | Solid svulst, voksenForente stater
-
BeiGeneRekrutteringSolid svulst | Avansert solid svulstForente stater, New Zealand, Australia, Kina
-
Anjali PawarRekrutteringSolid svulst | Solid svulst, barndomForente stater
Kliniske studier på Olaparib
-
Memorial Sloan Kettering Cancer CenterAktiv, ikke rekrutterendeSmåcellet lungekarsinom | Småcellet lungekreftForente stater
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdFullførtOndartet solid svulstBelgia
-
CSPC Ouyi Pharmaceutical Co., Ltd.FullførtFriske deltakereKina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaFullført
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)FullførtEpitelial eggstokkreftDanmark, Frankrike, Tyskland, Italia, Spania, Polen, Belgia, Canada, Storbritannia, Israel, Norge
-
Qilu Pharmaceutical Co., Ltd.Fullført
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological... og andre samarbeidspartnereRekruttering
-
SandozFullførtBrystkreft | EggstokkreftIndia
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological... og andre samarbeidspartnereAktiv, ikke rekrutterendeTilbakefallende eggstokkreft | Etter fullstendig eller delvis respons på platinabasert kjemoterapi | Platina følsom | BRCA mutertKorea, Republikken, Frankrike, Kina, Italia, Forente stater, Israel, Storbritannia, Canada, Japan, Tyskland, Brasil, Nederland, Belgia, Polen, Australia, Den russiske føderasjonen, Spania
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRekrutteringBRCA1-mutasjon | BRCA2-mutasjon | Homolog rekombinasjonsmangel | Ovarial neoplasma epitelialNederland